1. Home
  2. RNTX vs DIT Comparison

RNTX vs DIT Comparison

Compare RNTX & DIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.97

Market Cap

80.7M

Sector

Health Care

ML Signal

HOLD

Logo AMCON Distributing Company

DIT

AMCON Distributing Company

HOLD

Current Price

$72.90

Market Cap

79.1M

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNTX
DIT
Founded
2001
1981
Country
United States
United States
Employees
10
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Food Distributors
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
80.7M
79.1M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
RNTX
DIT
Price
$0.97
$72.90
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
583.4K
510.0
Earning Date
05-15-2026
04-20-2026
Dividend Yield
N/A
0.74%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,392,388,157.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
5.30
52 Week Low
$0.85
$68.00
52 Week High
$2.18
$126.50

Technical Indicators

Market Signals
Indicator
RNTX
DIT
Relative Strength Index (RSI) 45.08 37.18
Support Level N/A N/A
Resistance Level $1.33 $120.08
Average True Range (ATR) 0.09 1.49
MACD 0.01 -0.56
Stochastic Oscillator 55.14 31.96

Price Performance

Historical Comparison
RNTX
DIT

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

About DIT AMCON Distributing Company

Amcon Distributing Co is engaged in the wholesale and retail distribution of consumer products such as cigarettes, tobacco, confectionery, health food, and others. It operates in two segments: Wholesale distribution segment distributing consumer products to the retail outlets including convenience stores, grocery stores, liquor stores, drug stores and tobacco shops in the Central, Rocky Mountain, and Southern regions of the United States; and the Retail health food segment is a specialty retailer of natural/organic groceries and dietary supplements throughout the Midwest and Florida. The company earns a majority of the revenue from the Wholesale distribution segment.

Share on Social Networks: